







# NeuroNEXT Network


## Standard Operating Procedure (SOP) Development and Maintenance of SOPs Version 3.0 SOP NN GA 101

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:

<b>Signature and Date:</b>     I approve this document 14-Feb-2023   12:49:01 PM PST <small>C68AC8DD80334CF982AED1200765F147</small>	14-Feb-2023
<b>Name and Title:</b> Christopher S. Coffey, PhD (DCC Principal Investigator)	
<b>Signature and Date:</b>     I approve this document 13-Feb-2023   8:12:30 AM EST <small>9F8FE4180E504C6AB0A67B835E80C644</small>	13-Feb-2023
<b>Name and Title:</b> Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)	
<b>Signature and Date:</b>     I approve this document 13-Feb-2023   8:53:46 AM EST <small>58FE690F6BCA4F2390E3DA15BCE3F578</small>	13-Feb-2023
<b>Name and Title:</b> Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)	

**Signature and Date:**

DocuSigned by DIXIE ECKLUND  
 | I approve this document  
13-Feb-2023 | 9:59:58 AM PST  
7006AF622EFC40B6A067A08EC02591B6

13-Feb-2023

**Name and Title:** Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

**Signature and Date:**

DocuSigned by Stacey Grabert  
 | I approve this document  
22-Feb-2023 | 11:38:31 AM EST  
60CC52B0747A44E6B2208D8D880698C0

22-Feb-2023

**Name and Title:** Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

**Signature and Date:**

DocuSigned by Joan Ohayon  
 | I approve this document  
13-Feb-2023 | 11:16:04 AM PST  
72C6AAF8CC4485582ACA0700072901A

13-Feb-2023

**Name and Title:** Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

## NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR DEVELOPMENT AND MAINTENANCE OF SOPS

### 1. POLICY

The NeuroNEXT Data Coordinating Center (DCC) at the University of Iowa Clinical Trials Statistical and Data Management Center (CTSDMC) and Clinical Coordinating Center (CCC) at the Massachusetts General Hospital Neurology Clinical Trials Unit (NCTU) will develop network-wide Standard Operating Procedures (SOPs) in adherence with SOP NN GA 103 *Document Development and Change Control* procedures. SOPs are version-controlled documents that describe policies, procedures, roles, and responsibilities for specific functions or activities conducted by the Network.

Each SOP will have a unique number. All SOP numbering will consist of the following format – NN YY XXXX, where NN is always present, YY represents the two-letter SOP series code, and XXXX represents the three- or four-digit SOP number. SOPs are grouped into series according to content and purpose.

The entire set of NeuroNEXT SOPs will be reviewed on a periodic basis as needed. Existing SOPs may be revised, or new SOPs may be developed as needed between reviews. Senior Leadership at the DCC and CCC will assign a qualified staff member who is familiar with the area covered by the SOP to author or edit a specific SOP, and to generate a draft for review by applicable NeuroNEXT personnel. The final draft is then circulated to the Directors of the DCC and CCC, the NINDS NeuroNEXT Program Official, the CCC Director of Clinical Operations, the DCC Associate Director, and the CCC Director of Quality Assurance for review and signature approval.

New SOPs are assigned the version number 1.0, and subsequent revisions are versioned with the next consecutive whole version number. If, after review, it is determined that an existing SOP does not require revision, the current version number and effective date are retained. The Document History for that SOP is updated to indicate that the review took place, and that no revisions were required.

If revisions have been made to an existing SOP, the final revised version is dated, re-versioned, and signed by the signatories described above. The Issue Date of the SOP is the date of the last obtained signature. In order to allow time for training of applicable NeuroNEXT members, the Effective Date will be 45 calendar days after the Issue Date.

SOP signature approval pages are signed electronically and circulated between the required signatories via email. Electronic copies of currently-approved SOPs will be available to all applicable NeuroNEXT Network parties on the secure area of the NeuroNEXT website. Training on SOPs will occur in accordance with SOP NN GA 102 *SOP Training*.

The NINDS or other groups involved with conducting NeuroNEXT trials may develop policies and procedures that operate in conjunction with the NeuroNEXT CCC and DCC Network-wide SOPs, but these policies will not be under the purview of NeuroNEXT Network SOPs. The CCC and DCC will work with these groups to ensure that their policies do not conflict with NeuroNEXT Network SOPs.

### 2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E (R2). The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research within the Network regulated by FDA and/or applicable review committees.

### 3. ROLES AND RESPONSIBILITIES

Representatives from the CCC and DCC are responsible for identifying procedures that should be standardized across the NeuroNEXT Network, and for assigning appropriate individuals to draft SOPs. The CCC and DCC Leadership are responsible for reviewing and approving all Network SOPs.

As needed, representatives from the CCC and DCC are responsible for periodically reviewing all SOPs to determine if revisions are warranted, and for conducting interim reviews of selected SOPs if needed.

#### 4. APPLICABLE REGULATIONS AND GUIDELINES

ICH E6                      Guide to Good Clinical Practices

#### 5. REFERENCES TO OTHER APPLICABLE SOPS

This SOP applies to all NeuroNEXT Network SOPs.

#### 6. ATTACHMENTS AND REFERENCES

NN GA 101 - A              Document History

NN GA 101 - B              NeuroNEXT SOP Template

#### 7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CCC	Clinical Coordinating Center at Massachusetts General Hospital
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
GCP	Good Clinical Practices
ICH	International Council for Harmonisation
NINDS	National Institute of Neurological Disorders and Stroke
SOP	Standard Operating Procedure

#### 8. SPECIFIC PROCEDURES

##### A. Developing, Revising, and Approving NeuroNEXT Network SOPs

#	Who	Task	Attachment/ Reference	Related SOP
1.	Designated DCC and CCC members	Review all SOPs on a periodic basis, and as needed in the interim. Follow steps 8.A.2-9 to develop new SOPs or incorporate changes to current SOPs.		NN GA 103
2.	NeuroNEXT DCC/CCC	Identify appropriate procedures that are to be standardized across the NeuroNEXT Network.		
3.	NeuroNEXT DCC/CCC	If necessary, designate a qualified person to author or review a SOP.		
4.	SOP Author	Make necessary revisions to an existing SOP, or create a draft of a new SOP, utilizing the current approved NeuroNEXT template.	NN GA 101-B	NN GA 103
5.	SOP Author	Circulate the draft SOP to the reviewer(s) for comment.		NN GA 103
6.	SOP Reviewer(s)	Review the draft SOP and offer comments, if applicable.		

#	Who	Task	Attachment/ Reference	Related SOP
7.	SOP Author	Using document development and control procedures, incorporate all comments and circulate the final draft for review and approval by the appropriate signatories. <ul style="list-style-type: none"> <li>Assign version 1.0 to a new SOP.</li> <li>For revised SOPs, assign the next consecutive whole number as the new version number.</li> </ul>		NN GA 103
8.	DCC Director, CCC Director, NINDS NeuroNEXT Program Official, other applicable NeuroNEXT Leadership	Review the final draft of the SOP.		
9.	DCC Director, CCC Director, NINDS NeuroNEXT Program Official, and other signatories as appropriate	After final review, sign the signature page for the final version of the new or revised SOP to indicate approval. <ul style="list-style-type: none"> <li>An SOP is considered to be 'Issued' on the date of the last obtained signature.</li> <li>The Effective Date is 45 calendar days after the Issue Date.</li> <li>An SOP is considered to be in effect until a subsequent version is signature approved.</li> </ul>		
10.	SOP Lead Reviewer	If an SOP does not require revision: <ul style="list-style-type: none"> <li>retain the current version number and effective date;</li> <li>update the document history to indicate that the review took place and no revisions were required.</li> </ul>		
11.	Designated DCC and CCC members	As necessary, develop new SOPs on an interim basis following steps 8.A.2-9.		NN GA 103
12.	Designated DCC and CCC members, NINDS NeuroNEXT Program Official	If it becomes necessary to modify an existing SOP in the interim between reviews, follow steps 8.A.2-9, sign the modified version with the current date as the issue date, and assign the version number as the next whole number.		NN GA 103
13.	DCC DM or IT	When new SOPs are approved, or as needed, update applicable NeuroNEXT SOP review roles in the NeuroNEXT website.		
14.	DCC Lead Coordinator	Upload new or revised SOPs to the secure area of the NeuroNEXT website and inform applicable NeuroNEXT personnel that SOPs are available for review.		NN GA 102

Certificate Of Completion

Envelope Id: D0F27A3C8C43454B84ED07A23DC8FCFF Status: Completed
Subject: Complete with DocuSign: NN GA 101 Development and Maintenance of SOPs v3.0.docx
Source Envelope:
Document Pages: 5 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.159.130.82
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/13/2023 7:47:17 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey
christopher-coffey@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

Signature

Christopher Coffey

Timestamp

Sent: 2/13/2023 8:04:16 AM
Viewed: 2/14/2023 3:48:52 PM
Signed: 2/14/2023 3:49:04 PM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/14/2023 3:48:52 PM
ID: bc2a0dda-3d06-447b-8daf-759428fc20ad

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication (Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
13-Feb-2023 | 9:59:58 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/13/2023 8:04:17 AM
Viewed: 2/13/2023 12:57:08 PM
Signed: 2/13/2023 1:00:01 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/13/2023 12:57:08 PM
ID: 66e7b5b1-73e2-4462-8708-cb5f66168476

Signer Events	Signature	Timestamp
---------------	-----------	-----------

Joan Ohayon  
ohayonj@ninds.nih.gov  
Security Level: Email, Account Authentication (Required)

*Joan Ohayon*

Sent: 2/13/2023 8:04:18 AM  
Viewed: 2/13/2023 2:15:41 PM  
Signed: 2/13/2023 2:16:07 PM

Signature Adoption: Pre-selected Style  
Signature ID:  
72C6AAFD-8CC4-4855-82AC-A0700072901A  
Using IP Address: 71.178.185.120

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/13/2023 2:03:22 PM  
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase  
MCHASE@mgh.harvard.edu  
Sr Director, Clinical Trial Operations  
Insight OBO The Massachusetts General Hospital  
Security Level: Email, Account Authentication (Required)

*Marianne Chase*


Sent: 2/13/2023 8:04:17 AM  
Viewed: 2/13/2023 8:53:26 AM  
Signed: 2/13/2023 8:53:49 AM

Signature Adoption: Pre-selected Style  
Signature ID:  
58FE690F-6BCA-4F23-90E3-DA15BCE3F578  
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Not Offered via DocuSign

Merit Cudkowicz  
cudkowicz.merit@mgh.harvard.edu  
Chief of Neurology  
Security Level: Email, Account Authentication (Required), Logged in


DocuSigned by Merit Cudkowicz  
  
I approve this document  
13-Feb-2023 | 8:12:30 AM EST  
9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/13/2023 8:04:15 AM  
Viewed: 2/13/2023 8:12:19 AM  
Signed: 2/13/2023 8:12:33 AM

Signature Adoption: Pre-selected Style  
Signature ID:  
9F8FE418-0E50-4C6A-B0A6-7B835E80C644  
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password  
With Signing Reasons (on each tab):  
I approve this document

**Electronic Record and Signature Disclosure:**  
Accepted: 2/13/2023 8:12:19 AM  
ID: 863bc5e6-6e19-4caf-8e45-99b3d13bb213

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	  Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49  With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/13/2023 8:04:18 AM Viewed: 2/22/2023 11:38:22 AM Signed: 2/22/2023 11:38:34 AM
<b>Electronic Record and Signature Disclosure:</b> Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/13/2023 8:04:19 AM
Certified Delivered	Security Checked	2/22/2023 11:38:22 AM
Signing Complete	Security Checked	2/22/2023 11:38:34 AM
Completed	Security Checked	2/22/2023 11:38:34 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		



## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

### **How to contact Insight OBO The Massachusetts General Hospital:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu)

### **To advise Insight OBO The Massachusetts General Hospital of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

### **To request paper copies from Insight OBO The Massachusetts General Hospital**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

### **To withdraw your consent with Insight OBO The Massachusetts General Hospital**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [jhenrique@mgh.harvard.edu](mailto:jhenrique@mgh.harvard.edu) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.